Opinion

Video

Innovative Combination Strategies for Endometrial Cancer: Updates from LEAP and KEYNOTE-B21 Trials

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss emerging data from ongoing trials evaluating innovative combination strategies for endometrial cancer, including insights from the LEAP trial (pembrolizumab + lenvatinib) and the KEYNOTE-B21 trial (pembrolizumab + chemotherapy with or without radiotherapy). They also address treatment considerations for patients with sentinel lymph node–positive disease.

Video content above is prompted by the following:

  1. Briefly comment on other emerging data from ongoing trials evaluating other combination strategies in this setting.
  • LEAP (pembrolizumab + lenvatinib)
  • KEYNOTE-B21 (pembrolizumab + CT±RT)
  • Spoke on sentinel lymph node–positive treatment
Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment